On November 25, 2025, Predictive Oncology Inc. announced that shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing the available shares by 1,000,000. Additionally, shareholders ratified the appointment of KPMG LLP as the independent auditor and voted on the election of directors and compensation of executives.